Neurology Central

Investigational gene therapy licensed for Parkinson’s disease: industry news round-up

This week’s industry news round-up reveals the latest updates around spinal muscular atrophy, Parkinson’s disease and acute stroke. Find out more about our selection of the highlights below.
Our pick of the headlines include:

Roche discontinues work on olesoxime for spinal muscular atrophy

Roche (Basel, Switzerland) has disclosed that it has ended work on olesoxime – an oral compound intended to protect motor neurons – for the treatment of spinal muscular atrophy (SMA), having faced “many difficulties” during the development of the experimental neuroprotective drug.

In a statement shared online through TreatSMA (Royal Tunbridge Wells, UK), Roche discloses the most recent results of the OLEOS Phase II trial (NCT02628743), an open-label study in Europe on the long-term safety, tolerability and efficacy of olesoxime in type 2 and non-ambulatory type 3 SMA patients.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.